Literature DB >> 7271273

Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and rhesus monkeys.

E A Ferrara, J S Oishi, R W Wannemacher, E L Stephen.   

Abstract

Ribavirin has been shown to have broad-spectrum antiviral. To study its tissue distribution and disappearance rate, a single dose of 10 mg/kg which contained 10 microCi of [14C]ribavirin was injected intravenously into rhesus monkeys and intramuscularly into monkeys and rats. Except for peak plasma concentrations and the initial phases of the plasma disappearance and urine excretion curves, no significant difference was observed between plasma, tissue, or urine values for intramuscularly or intravenously injected monkeys. Plasma disappearance curves were triphasic; plasma concentrations of ribavirin were similar for both monkeys and rats. Rats excreted ribavirin in the urine more rapidly and to a greater extent (82% excreted in 24 h) than did monkeys (60% excreted in 72 h). In the rat, only 3% of the injected [14C]ribavirin was detected in expired CO2. Therefore, for both species, urine was the major route for the elimination of labeled ribavirin and its metabolites from the body. In monkeys, the amount of parent drug in blood cells increased through 48 h and remained stable for 72 h, whereas in rats, ribavirin decreased at a rate similar to the plasma disappearance curve. Concentrations of ribavirin at 8 h were consistently higher in monkeys than in rats for all tissues except the brain. Thus, these differences in blood cellular components and organ content and in urine excretion suggested that there was greater tissue retention of ribavirin in monkeys than in rats.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7271273      PMCID: PMC181605          DOI: 10.1128/AAC.19.6.1042

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  The enzymic conversion of 1,2,4-triazole-3-carboxamide to ribavirin-5'-phosphate and its relationship to the proposed mechanism of action.

Authors:  D G Streeter; J P Miller; R K Robins; L N Simon
Journal:  Ann N Y Acad Sci       Date:  1977-03-04       Impact factor: 5.691

2.  The relationship between the metabolism of ribavirin and its proposed mechanism of action.

Authors:  J P Miller; L J Kigwana; D G Streeter; R K Robins; L N Simon; J Roboz
Journal:  Ann N Y Acad Sci       Date:  1977-03-04       Impact factor: 5.691

3.  Experimental Lassa fever virus infection successfully treated with ribavirin.

Authors:  E L Stephen; P B Jahrling
Journal:  Lancet       Date:  1979-02-03       Impact factor: 79.321

4.  Double-blind evaluation of oral ribavirin (Virazole) in experimental influenza A virus infection in volunteers.

Authors:  C R Magnussen; R G Douglas; R F Betts; F K Roth; M P Meagher
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

5.  Double-blind clinical assessment of ribavirin (virazole) in the prevention of induced infection with type B influenza virus.

Authors:  Y Togo; E A McCracken
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

6.  Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A.

Authors:  A Cohen; Y Togo; R Khakoo; R Waldman; M Sigel
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

7.  Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.

Authors:  R W Sidwell; J H Huffman; G P Khare; L B Allen; J T Witkowski; R K Robins
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

8.  The significance and mechanism of an increased serum phenylalanine-tyrosine ratio during infection.

Authors:  R W Wannemacher; A S Klainer; R E Dinterman; W R Beisel
Journal:  Am J Clin Nutr       Date:  1976-09       Impact factor: 7.045

9.  Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin.

Authors:  P B Jahrling; R A Hesse; G A Eddy; K M Johnson; R T Callis; E L Stephen
Journal:  J Infect Dis       Date:  1980-05       Impact factor: 5.226

10.  Activity of amantadine, rimantadine, and ribavirin against swine influenza in mice and squirrel monkeys.

Authors:  G H Scott; E L Stephen; R F Berendt
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

View more
  15 in total

1.  Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys.

Authors:  Chin-Chung Lin; Li-Tain Yeh; Trong Luu; David Lourenco; Johnson Y N Lau
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 2.  The application and mechanism of action of ribavirin in therapy of hepatitis C.

Authors:  Emmanuel Thomas; Marc G Ghany; T Jake Liang
Journal:  Antivir Chem Chemother       Date:  2012-09-25

3.  Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.

Authors:  S Khakoo; P Glue; L Grellier; B Wells; A Bell; C Dash; I Murray-Lyon; D Lypnyj; B Flannery; K Walters; G M Dusheiko
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

4.  Mechanism of La Crosse virus inhibition by ribavirin.

Authors:  L F Cassidy; J L Patterson
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

5.  Effect of ribavirin and tributylribavirin on argentine hemorrhagic fever (Junin virus) in guinea pigs.

Authors:  R H Kenyon; P G Canonico; D E Green; C J Peters
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

6.  Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection.

Authors:  Akihito Tsubota; Yuichi Hirose; Namiki Izumi; Hiromitsu Kumada
Journal:  Br J Clin Pharmacol       Date:  2003-04       Impact factor: 4.335

Review 7.  Biochemistry and clinical applications of ribavirin.

Authors:  B E Gilbert; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

8.  Pharmacokinetics of ribavirin aerosol in mice.

Authors:  B E Gilbert; P R Wyde
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

9.  Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice.

Authors:  M Kende; C R Alving; W L Rill; G M Swartz; P G Canonico
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

10.  Disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin in rat and monkey red blood cells and liver.

Authors:  Chin-Chung Lin; David Lourenco; Guifen Xu; Li-Tain Yeh
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.